AstraZeneca Scraps Plan To Expand Vaccine Plant In UK

'AstraZeneca ditches vaccine plant' and Trump's EU tariff threat
The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says executives have warned that policies pursued by the government will make the UK a less attractive place to invest.
AstraZeneca scraps plan to expand vaccine plant in the UK in blow to government
Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in northwest England.
AstraZeneca scraps £450m vaccine plant in Liverpool after Labour funding cut
The pharmaceutical giant says the new Labour government has offered less investment than their Conservative predecessors.
AstraZeneca cancels UK plant after subsidies cut
Scrapping the £450 million vaccine plant deals a major blow to the Labour government’s economic revival plans.
AstraZeneca Calls Off Vaccine Hub Investment Over UK Funding
AstraZeneca Plc abandoned plans to invest £450 million ($558 million) in a UK vaccine manufacturing plant, following protracted wrangling with the new Labour government over the level of state funding for the site.
AstraZeneca ditches UK investment over cut in state support
AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England, citing a cut in British government support. The decision to d
AstraZeneca ditches £450m investment in UK plant
AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Liverpool, blaming a reduction in government support. The pharmaceutical giant has announced its decision just two days after Chancellor Rachel Reeves set out Labour's plan to go "further and faster" to boost economic growth.
AstraZeneca terminates plan to build $558 mln UK vaccine plant
AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.
AstraZeneca ditches plan to build new UK vaccine plant
AstraZeneca is pulling out of its plans to build a £450mn UK vaccine manufacturing plant after months of wrangling with British officials about state investment for the Merseyside project, in a major blow to Prime Minister Sir Keir Starmer’s government.
AstraZeneca cancels £450m investment in UK after dispute over Government support
The pharmaceutical giant claimed the Labour Government failed to match its predecessor’s offer of help for the Merseyside investment.
Mayor wants to continue talks with AstraZeneca
Metro Mayor Steve Rotheram has said he is hoping to restart talks with AstraZeneca after it scrapped plans to invest £450m in ...
AstraZeneca abandons £450m vaccine factory in blow to Reeves
AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start ...
AstraZeneca cancels £450m UK investment after dispute over Government support
Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous ...
Blow for Reeves as AstraZeneca ditches £450m investment
AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Merseyside, blaming a reduction in government support. The pharmaceutical giant announced its decision just ...
FierceBiotech2d
AstraZeneca antibody protects macaques from severe bird flu, suggesting prophylactic potential in case of outbreak
All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...
AstraZeneca, Daiichi win EU backing for breast cancer drug Dato-DXd
AstraZeneca (AZN) stock in focus as its partner Daiichi Sankyo (DSNKY) wins EU backing for their jointly developed breast ...
Budget 2025: Pfizer, Novartis, AstraZeneca to benefit from BCD exemptions; pharma stocks mixed
Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...
AstraZeneca move leaves Reeves under the weather
The government may have strong arguments for denying AstraZeneca's demands, but they may be harder to sustain given the sector - high-growth life sciences; the company - Britain's largest by market ...